nach oben

Autoimmunity Highlights

Erschienen in:

01.06.2014 | Review Article

Treatment of the antiphospholipid syndrome

verfasst von: Monica Galli

Erschienen in: Autoimmunity Highlights | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.

Galli M, Comfurius P, Maassen C et al (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 334:1544–1547CrossRef

McNeil HP, Simpson RJ, Chesterman CN, Krilis SA (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87:4120–4124PubMedPubMedCentralCrossRef

Matsuura E, Igarashi Y, Fujimoto M et al (1990) Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336:177–178PubMedCrossRef

Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA (1991) Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66:629–632PubMed

Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM (1992) Anticoagulant activity of anti-β2-glycoprotein I is potentiated by a distinct subgroup of anti-cardiolipin antibodies. Thromb Haemost 68:297–300PubMed

Horbach DA, van Oort E, Derksen RHWM, de Groot PG (1998) The contribution of anti-prothrombin antibodies to lupus anticoagulant activity. Thromb Haemost 9:790–796

Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthr Rheum 42:1309–1311CrossRef

Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306PubMedCrossRef

Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemos 74:1185–1190

10.

Pengo V, Tripodi A, Reber G et al (2009) Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 7:1737–1740PubMedCrossRef

11.

Willis R, Pierangeli S (2011) Pathophysiology of the antiphospholipid syndrome. Autoimmun Highlights 2:35–52CrossRef

12.

Galli M, Ruggeri M, Barbui T (1998) Differential effects of antiβ2-Glycoprotein I and anti-prothrombin antibodies on the anticoagulant activity of activated protein C. Blood 91:1999–2004PubMed

13.

Rand JH, Wu XX, Quinn AS, Taatjes DJ (2010) The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 19:460–469PubMedCrossRef

14.

Salemink I, Blezer R, Willems GM et al (2000) Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 84:653–656PubMed

15.

Galli M, Willems GW, Rosing J et al (2005) Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 129:240–247PubMedCrossRef

16.

Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368:1033–1048PubMedCrossRef

17.

Von Landberg P (2011) Toll-like receptors play a crucial part in the pathophysiological activity of antiphospholipid antibodies. Autoimmun Highlights 2:53–57CrossRef

18.

de Laat BH, Derksen RHWM, Urbanus R, Roest M, de Groot PG (2004) β2-GPI-dependent lupus anticoagulant activity highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104:3598–3602PubMedCrossRef

19.

de Laat BH, Derksen RHWM, Urbanus R, Roest M, de Groot PG (2005) IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105:1540–1545PubMedCrossRef

20.

de Laat BH, Derksen RHWM, Van Lummel M, Pennings MT, de Groot PG (2006) Pathogenic anti-β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change. Blood 107:1916–1924PubMedCrossRef

21.

Agar C, Van Os GM, Morgelin M et al (2010) Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 116:1336–1343PubMedCrossRef

22.

Ioannou I, Zhang YJ, Qi M et al (2011) Novel Assays of thrombogenic pathogenicity in the Antiphospholipid Syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-Glycoprotein I. Arthr Rheum 63:2774–2782CrossRef

23.

Ioannou Y, Zhang JY, Passam FH et al (2010) Naturally occurring free thiols within β2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells and regulation of oxidative stress induced cell injury. Blood 116:1961–1970PubMedCrossRef

24.

Gharavi AE, Pierangeli SS, Harris EN (2001) Origin of the antiphospholipid antibodies. Rheum Dis Clin North Am 27:551–563PubMedCrossRef

25.

Van OSGM, Meijers JC, Agar C et al (2011) Induction of anti-β2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost 9:2447–2456CrossRef

26.

Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthr Rheum 46:1019–1027CrossRef

27.

Cervera R, Khamashta MA, Shoenfeld Y et al (2009) Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1,000 patients. Ann Rheum Dis 68:1428–1432PubMedCrossRef

28.

Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827–1832PubMedCrossRef

29.

Galli M, Luciani D, Bertolini G, Barbui T (2003) Antiβ2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 102:2717–2723PubMedCrossRef

30.

Opatrny L, David M, Kahn SR, Shrier I, Rey E (2006) Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune diseases: a metaanalysis. J Rheumatol 33:2214–2221PubMed

31.

Previtali S, Barbui T, Galli M (2002) Anti-β2-glycoprotein I and antiprothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case–control study. Thromb Haemost 88:729–732PubMed

32.

Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S (2005) Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 93:1147–1152PubMed

33.

Ruffatti A, Tonello M, Del Ross T et al (2006) Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 96:337–341PubMed

34.

Pengo V, Ruffatti A, Legnani C et al (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8:237–242PubMedCrossRef

35.

Pengo V, Ruffatti A, Legnani C et al (2011) Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicentre prospective study. Blood 118:4714–4718PubMedCrossRef

36.

Lee EY, Lee CK, Lee TH et al (2003) Does the anti-β2-glycoprotein I antibody provide additional information in patients with thrombosis? Thromb Res 111:29–32PubMedCrossRef

37.

Male C, Foulon D, Hogendoorn H et al (2005) Predictive values of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 106:4152–4158PubMedCrossRef

38.

Forastiero R, Martinuzzo M, Pombo G et al (2005) A prospective study of antibodies to β2-GPI and prothrombin and risk of thrombosis. J Thromb Haemost 3:1231–1238PubMedCrossRef

39.

De Laat B, Pengo V, Pabinger I et al (2009) The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 7:1767–1773PubMedCrossRef

40.

Erkan D, Harrison MJ, Levy M et al (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthr Rheum 56:2882–2891CrossRef

41.

Finazzi G, Brancaccio V, Moia M et al (1996) Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 100:530–536PubMedCrossRef

42.

Ruffatti A, Ross TD, Ciprian M et al (2011) Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 70:1083–1086PubMedCrossRef

43.

Cuadrado MJ, Bertolaccini ML, Seed PT (2013) Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology E-pub October 4

44.

Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376(1498–150):9

45.

Derksen RHWM, de Groot PG (2010) Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus 19:470–474PubMedCrossRef

46.

Punnialingam S, Khamashta MA (2013) Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop? Curr Rheumatol Rep 15:318–325PubMedCrossRef

47.

Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I et al (2011) Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20:206–218PubMedCrossRef

48.

Crowther MA, Ginsberg JS, Julian J et al (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. N Engl J Med 349:1133–1138PubMedCrossRef

49.

Finazzi G, Marchioli R, Brancaccio V et al (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3:848–853PubMedCrossRef

50.

Levine SR, Brey RL, Tilley BC, APASS Investigators et al (2004) Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291:576–584PubMedCrossRef

51.

Erkan D, Vega JA, Ramon G, Kozora E, Lockshin MD (2013) A pilot open-label phase II trial of Rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthr Rheum 65:464–475CrossRef

52.

Statkute L, Traynor A, Oyama Y et al (2005) Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood 106:2700–2709PubMedCrossRef

53.

Favaloro EJ, Wong RCW (2010) The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours? Autoimmun Highlights 1:5–14CrossRef

54.

Espinosa G, Cervera R (2010) Management of the antiphospholipid syndrome. Autoimmun Highlights 1:15–22CrossRef

55.

Rai RS, Regan L, Clifford K et al (1995) Antiphospholipid antibodies and beta2-glycoprotein I in 500 women with recurrent miscarriage: result of a comprehensive screening approach. Hum Reprod 10:2001–2005PubMed

56.

Rai RS, Clifford K, Cohen H et al (1995) High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 10:3301–3304PubMed

57.

Galarza-Maldonado C, Kourilovitch MR, Perez-Fernandez O et al (2012) Obstetric antiphospholipid syndrome. Autoimmun Rev 11:288–295PubMedCrossRef

58.

Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(suppl):691S–736S

59.

Bramham K, Hunt BJ, Germain S et al (2010) Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 19:58–64PubMedCrossRef

60.

Ruffatti A, Tonello M, Visentin S et al (2011) Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case–control study. Rheumatology 50:1684–1689PubMedCrossRef

61.

Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V (2009) Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 123:482–487PubMedCrossRef

62.

Cervera R, Espinosa G (2012) Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Haemost 38:333–338CrossRef

63.

Cervera R (2012) CAPS registry. Lupus 21:755–757PubMedCrossRef

64.

Asherson RA, Cervera R, Piette JC et al (2001) Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80:355–376CrossRef

65.

Bucciarelli S, Espinosa G, Cervera R et al (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthr Rheum 54:2568–2576CrossRef

66.

Asherson RA, Cervera R, de Groot PR et al (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530–534PubMedCrossRef

67.

Erkan D, Asherson RA, Espinosa G et al (2003) Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 62:530–533PubMedPubMedCentralCrossRef

68.

Berman H, Rodriguez-Pintò I, Cervera R et al (2013) Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12:1085–1090PubMedCrossRef

69.

Broder A, Putterman C (2013) Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol 40:30–33PubMedPubMedCentralCrossRef

70.

Schmidt-Tanguy A, Voswinkel J, Henrion D et al (2013) Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost 11:1927–1929PubMed

71.

Lopez-Pedrera C, Ruiz-Limon P, Pedrera A et al (2011) Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 70:675–682PubMedCrossRef

Titel: Treatment of the antiphospholipid syndrome
verfasst von: Monica Galli
Publikationsdatum: 01.06.2014
Verlag: Springer International Publishing
Erschienen in: Autoimmunity Highlights / Ausgabe 1/2014
Print ISSN: 2038-0305
Elektronische ISSN: 2038-3274
DOI: https://doi.org/10.1007/s13317-013-0056-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Treatment of the antiphospholipid syndrome

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin